Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
09:45pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
GlaxoSmithKline (GSK) closed the most recent trading day at $46.85, moving +0.69% from the previous trading session.
Glaxo (GSK) to Buy Sierra for $1.9B, Add Hematology Drug
02:18pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
The acquisition of Sierra Oncology (SRRA) will add late-stage oncology pipeline candidate, momelotinib to Glaxo's (GSK) hematology pipeline.
Why Sierra Oncology Stock Is Soaring Today
12:14pm, Wednesday, 13'th Apr 2022 The Motley Fool
GlaxoSmithKline is adding another cancer asset to its portfolio by acquiring U.S.-based Sierra Oncology.
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
06:36am, Wednesday, 13'th Apr 2022 MarketWatch
Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
03:20pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
This Exciting Biotech Stock Could Be Your Next 10-Bagger
10:00am, Sunday, 10'th Apr 2022 The Motley Fool
The company's drug development program is the major key to success.
3 Pharmaceutical Stocks With Awesome Futures
11:15am, Saturday, 09'th Apr 2022 The Motley Fool
The market is so pessimistic about anything COVID-related that everything has gotten super cheap.
3 Things About Pfizer That Smart Investors Know
03:07pm, Friday, 08'th Apr 2022 The Motley Fool
The next few years might get a little bumpy.
Antibody Treatments for COVD-19 Face Challenges in the U.S.
01:31pm, Friday, 08'th Apr 2022 Zacks Investment Research
With the emergence of the highly transmissible Omicron variant, the authorized antibody treatments of companies like Vir Biotechnology (VIR), Glaxo (GSK) and Regeneron (REGN) suffer setbacks due to a
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
09:50pm, Thursday, 07'th Apr 2022 Zacks Investment Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $46.23, marking a +1.12% move from the previous day.
BA.2 subvariant of omicron accounted for almost 94% of global cases in latest week, the latest sign of how dominant it has become
11:57am, Thursday, 07'th Apr 2022 MarketWatch
The omicron variant of the coronavirus that causes COVID-19 accounted for 99.8% of global new cases in the latest week, the World Health Organization said Wednesday, and the BA.2 subvariant accounted
VIR Stock Down on Another Setback for COVID-19 Antibody
04:25pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
VIR and partner Glaxo suffer a setback as the FDA determines that sotrovimab is no longer authorized for use in the United States for COVID-19.
3 CEOs to Invest In
01:00am, Saturday, 02'nd Apr 2022 The Motley Fool
Looking for a healthcare stock with strong leadership? Our roundtable likes Immunocore, Axsome Therapeutics, and GlaxoSmithKline.
Why Shares of Vir Biotechnology Rose 20.4% This Week
04:43pm, Friday, 01'st Apr 2022 The Motley Fool
Joining the S&P SmallCap 600 could boost the company's profile.
